Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer

Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer - Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009085

Enrollment

Registered

2012-11-01

Start date

2012-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable Advanced and Recurrent Pancreatic cancer

Interventions

OCV-101 1mL will be administered by subcutaneous injection on days, 1,8,15 and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who are under trial treatment in SE01. 2) Patients who wish to continue trial treatment. And there is no obvious disease progression, also it is judged that there is clinical benefit by continuing trial treatment. 3) ECOG Performance Status must be 0 to 2. 4) Patient must have signed the consent form.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026